Stoke Therapeutics downgraded at TD Cowen after STK-001 update

As previously reported, TD Cowen downgraded Stoke Therapeutics to Market Perform from Outperform following the company’s update with new safety and efficacy data from patients treated with STK-001 in the two ongoing Phase 1/2a studies and the SWALLOWTAIL open-label extension study in children and adolescents with Dravet syndrome. Multiple 30 and 45 mg doses do not seem to boost seizure reduction relative to the prior data cut, while multiple 70 mg doses are still on hold in the U.S. given safety concerns and the limited therapeutic window raises questions about the commercial viability in the ultra-orphan market, the analyst tells investors.